There is growing evidence that suggests NOX4 as a potential target for the treatment of ARDS/ALI patients during both the acute and the proliferative stage (Manoury et al., 2005; Bernard et al., 2017). This evidence concerns the gene NOX4 and acute respiratory distress syndrome.